Case Study: Filing in 12 Countries on a Small Budget — A PCT Strategy

An inventor used the PCT as an options strategy — designating 12 countries at filing but entering national phase in only 5, based on commercial evidence gathered during the 30-month window. This case study shows how the PCT's time-buying function saves money by letting you invest only where the market justifies it.

This case study is a realistic composite. Names and specific details have been changed.

The Situation

Fatima invented a novel water-saving irrigation valve for commercial agriculture. Her PCT application, filed at month 12 after a US provisional, designated all PCT member states — which it does by default. Her initial target list included 12 countries where she believed the valve had commercial potential: US, EU (via EPO), China, India, Brazil, Australia, Japan, South Korea, Mexico, Turkey, Saudi Arabia (via GCC), and South Africa.

Filing national phase in all 12 jurisdictions would have cost approximately $95,000 in translation, attorney, and filing fees — far beyond her $35,000 IP budget.

The 30-Month Window

During the 30 months between her PCT filing and the national phase deadline, Fatima used the time strategically:

Months 12–18: The International Search Report (ISR) came back with a positive Written Opinion — the examiner found novelty and inventive step in the main claims. This gave Fatima confidence that national prosecution would be straightforward in most offices.

Months 18–24: Fatima attended two agricultural trade shows — SIMA in Paris and the Saudi Agriculture exhibition in Riyadh. She gauged interest from distributors and received two letters of intent: one from a French agricultural equipment distributor and one from a Saudi irrigation company.

Months 24–28: She conducted informal market research. The Indian market was price-sensitive — her valve's price point was 3× existing options, and Indian competitors were already selling adequate alternatives. The Brazilian market was promising but her contact there went silent. The Japanese and South Korean markets showed minimal interest — both countries had limited commercial agriculture at the scale her valve addressed. The Australian market was strong but small — the total addressable market was perhaps $500,000/year, which could not justify $8,000 in national phase costs.

Month 29: Fatima made her decisions.

The National Phase Decisions

Total national phase cost: $24,000 — versus the $95,000 it would have cost to enter all 12. Fatima saved $71,000 by using the PCT window to gather evidence before committing.

The Outcome

The US patent was granted under Track One in 10 months. PPH requests accelerated prosecution at the EPO and GCC. The Chinese utility model registered in 8 months. By Year 3, Fatima had granted patents in her three most commercially important markets plus fast bridge protection in China.

The French distributor signed a non-exclusive licence at 4% of net sales. The Saudi company entered licensing discussions, with ICV requirements making Fatima's GCC-filed patent a competitive advantage in government irrigation tenders.

The countries she skipped showed no significant commercial activity in the following three years — confirming that the decisions to skip were correct.

The Lessons

The PCT is an options strategy, not a commitment. Filing a PCT costs $4,000–$5,000 and preserves rights in more than 150 countries for 30 months. Entering national phase in each country costs $4,000–$10,000 per country. The PCT lets you buy time to decide where to invest — and where not to.

Use the 30-month window actively. The window is not dead time — it is intelligence-gathering time. Attend trade shows, approach distributors, gauge market interest, and assess pricing viability. The data you gather determines which national phases are worth the investment.

The ISR informs your prosecution budget. A positive ISR gives confidence to enter multiple national phases. A negative ISR (finding close prior art) might cause you to enter fewer jurisdictions — or to amend claims before national phase entry, reducing the risk of expensive prosecution rounds.

Skip markets without evidence. "Brazil might be good" is not a reason to spend $8,000 on national phase entry. A letter of intent, a distributor relationship, or concrete market data is a reason. Without evidence of commercial potential, the money is better spent on prosecution in confirmed markets.

You can still file directly later. Fatima skipped Turkey at the national phase deadline but retained the option to file directly in Turkey later — she would lose the PCT priority date, but if the Turkish market developed after her PCT publication, she could assess whether a direct Turkish filing (without priority) was still worthwhile based on the prior art landscape.

Sources

1. WIPO PCT System — The international filing system central to Fatima's strategy
2. USPTO Track One Prioritized Examination — Accelerated US examination used after national phase entry
3. USPTO Patent Prosecution Highway (PPH) — Accelerated prosecution based on favourable ISR results
4. EPO Patent Filing — European national phase entry procedures
5. GCC Patent Office — Regional patent office for GCC national phase entry